Sara Ansaloni
About Sara Ansaloni
Sara Ansaloni is a Senior Manager at Mammoth Biosciences, where she has worked since 2022. She has a strong background in biotechnology and molecular biology, with previous roles as a Senior Scientist and various academic positions.
Work at Mammoth Biosciences
Sara Ansaloni currently serves as a Senior Manager at Mammoth Biosciences, a position she has held since 2022. Prior to this role, she worked as a Senior Scientist at the same company from 2020 to 2022. During her tenure in Brisbane, California, she organized and communicated with cross-functional teams within the biotech and medical devices industry, contributing to various projects and initiatives.
Education and Expertise
Sara Ansaloni earned her Bachelor of Science degree in Industrial Biotechnology from the University of Modena and Reggio Emilia, where she studied from 1997 to 2002. She later pursued a PhD in Cell/Cellular and Molecular Biology at Drexel University, completing her studies from 2005 to 2010. Her academic background provides her with a strong foundation in biotechnology and molecular biology, which she applies in her professional roles.
Background
Sara Ansaloni has a diverse professional background that includes significant roles in academia and industry. She worked as a Visiting Scholar at the University of Pennsylvania from 2003 to 2005 and as a Research Assistant at Drexel University from 2005 to 2010. Additionally, she served as a Graduate Teaching Assistant at Drexel University from 2005 to 2007, gaining experience in both research and education.
Achievements
Sara Ansaloni has co-authored an issued patent for new anti-hemophilic factors formulations. She has experience in designing pharmacokinetic/pharmacodynamic (PK/PD) pre-clinical studies and validating antibody-based and in vitro assays. Her research includes investigating complement system inhibition and blood perfusion in melanomas using in vivo murine models, as well as utilizing ultrasound live imaging for measuring blood flow. She has also submitted an investigational device exemption (IDE) application to the FDA.